LUMI AI Factory Selects IQM's Staged Path to Europe's First Superconducting Quantum Computer With Logical Qubits
10.9.2026 10:08:00 EEST | Business Wire | Press release
IQM Quantum Computers (Nasdaq: IQMX) today announced its upgrade path for a logical-qubit-capable quantum computer. The deployment to the LUMI AI Factory, led by CSC – IT Center for Science, will support R&D efforts toward fault-tolerant quantum computing and advancements in hybrid computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910712470/en/
UMI AI Factory selects IQM's staged path to Europe's first superconducting quantum computer with logical qubits
The system, named LUMI-IQ, is an integral part of the wider LUMI AI Factory initiative, and is jointly funded by the EuroHPC Joint Undertaking and the participating countries: Finland, Czechia, Norway, and Poland. LUMI-IQ will be hosted in CSC’s new data center in Kajaani, Finland.
LUMI-IQ will be delivered in three steps: the first installation of an IQM Halocene H4 system in 2027 with 150 physical qubits and early quantum error correction capabilities. The system will be upgraded in 2028 to lower logical error rates and enable real time error correction. The final upgrade is installation of IQM Halocene H5 system in 2029. These upgrades equip the system towards early fault tolerant quantum computing.
After the final upgrade, LUMI-IQ will be capable of fast real time feedback sustaining logical qubits and enabling full logical operations between the qubits, including lattice surgery and T-gate teleportation. With distance 3 surface code and colour code, the system will enable computations with up to 9 logical qubits. Additionally, the is capable encoding logical qubits up to distance 11 with surface code and distance 9 with color code.
Logical qubits created by combining multiple physical qubits through quantum error correction are significantly more stable and reliable than physical qubits alone, making them essential to running the longer, more complex calculations required for real-world quantum applications.
This phased delivery reflects IQM's development roadmap toward fault-tolerant quantum computing, delivering error-corrected systems with high-precision logical qubits. It allows customer a capital efficient way to benefit from IQM´s ambitious error correction roadmap and a continuous integration into their existing compute infrastructure.
“Owning an upgradeable quantum computer let´s CSC and the LUMI AI Factory integrate the system into their own AI and HPC infrastructure. That's what lets a real ecosystem grow: researchers building on infrastructure they control, inside one of the most capable computing environments anywhere,” said Jan Goetz, CEO and Co-founder of IQM Quantum Computers. “That kind of ownership is exactly what Europe needs right now — not just access to quantum computing, but the ability to shape its direction, build local expertise, and push the frontiers of advanced computing.”
The system will be integrated into the LUMI-AI computing environment. Together, LUMI-IQ and LUMI-AI will form a leading hybrid computing platform, enabling workloads that combine HPC, AI, and quantum computing.
This integrated approach is expected to enable new forms of scientific workloads that combine traditional simulation, machine learning, and quantum algorithms — opening new research avenues for European end-users.
“The greatest potential lies in combining the complementary strengths of AI, high-performance computing, and quantum computing. Logical qubits make quantum calculations more reliable, while AI and HPC provide the scale, data processing and orchestration needed around them. The LUMI AI Factory allows European researchers to develop innovative hybrid approaches in a world-class computing environment,” said Kimmo Koski, CEO of CSC – IT Center for Science.
About IQM Quantum Computers
IQM Quantum Computers (Nasdaq: IQMX) is a global leader in superconducting quantum computers, delivering full-stack quantum systems and cloud platform access to enterprises, research institutions, universities, high-performance computing centers, and national laboratories worldwide. IQM's open, modular architecture allows customers to own, operate, and integrate quantum systems directly into their own infrastructure, building lasting technical capability rather than relying solely on remote access. Founded in 2018, IQM is headquartered in Espoo, Finland, with major operations in Munich, Germany, and has sold more quantum systems than any other manufacturer to date. IQM employs over 450 people and operates across Europe, Asia, and North America. IQM is the first publicly listed European quantum company on Nasdaq Stock Market.
About CSC – IT Center for Science
CSC is a Finnish center of expertise in ICT that provides world-class services for research, education, culture, public administration, and enterprises, to help them thrive and benefit society at large. www.csc.fi
LUMI AI Factory:
The LUMI AI Factory is a leading-edge service infrastructure and expert support centre designed to accelerate AI innovation across Europe. The LUMI AI Factory delivers a seamless, open AI solution that integrates world-class supercomputing, high-value data, and top-tier AI expertise. It is the biggest AI Factory of the European Union. www.lumi-ai-factory.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20260910712470/en/
Contacts
IQM Media contact:
Email: press@iqm.tech
Mobile: +358 (0) 50 479 0845
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom